Clinical Trials Logo

Clinical Trial Summary

The goal of this multicentre randomized controlled trial is to investigate if a very short-course of antibiotics (1 day) for cholangitis after adequate drainage is non-inferior with respect to clinical cure in comparison with a standard course of antibiotics (4 to 7 days). Secondary objectives include: - Will a one-day course of antibiotics for cholangitis after adequate drainage be non-inferior with respect to relapse of cholangitis and mortality in comparison with a standard course of antibiotics? - Will a one-day course of antibiotics for cholangitis after adequate drainage result in less adverse drug events in comparison with a standard course of antibiotics? - Will a one-day course of antibiotics for cholangitis after adequate drainage reduce length of hospital stay? - Will a one-day course of antibiotics for cholangitis after adequate drainage improve quality of life? - Will a one-day course of antibiotics for cholangitis after adequate drainage be cost-effective?


Clinical Trial Description

Acute cholangitis is an infection of the biliary tract which is managed with biliary drainage and antibiotic therapy (ABT). Currently the international Tokyo Guidelines 2018 (TG18) recommend 4 to 7 days of ABT after source control. The national SWAB guideline of 2020 suggests a course of one to 3 days after biliary drainage. There are no randomized studies to guide the duration of ABT for acute cholangitis. Our recent retrospective study in the Netherlands showed that a short course of ABT seems safe and more evidence is available showing that other bacterial infections, including abdominal and bloodstream infections, can be treated with a short antibiotic course than previously assumed. Hence, the hypothesis is that a very short-course of ABT for acute cholangitis is non-inferior to a course of 4 to 7 days after adequate biliary drainage. This study is designed as a multicenter non-inferiority randomized controlled trial. Patients will be randomly assigned to the intervention group (one day of antibiotic therapy after ERCP) or the comparator group (4 to 7 days of antibiotic therapy after ERCP). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05750966
Study type Interventional
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact
Status Recruiting
Phase N/A
Start date July 19, 2023
Completion date September 1, 2026

See also
  Status Clinical Trial Phase
Completed NCT02917408 - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Withdrawn NCT02543957 - Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
Completed NCT02461147 - Prospective Validation of "Cholecystectomy First" Strategy for Gallstone Migration
Completed NCT01824186 - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy N/A
Terminated NCT00990366 - Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve N/A
Completed NCT02594891 - Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis N/A
Terminated NCT01142921 - The Patency Period of the New Plastic Anti-reflux Biliary Stent N/A
Completed NCT03104582 - Best Biliary Drainage Option in Advanced Klatskin Tumor N/A
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Terminated NCT02034279 - The INFECIR-2 Albumin Prevention Study Phase 4
Completed NCT04671095 - Single Use ERCP Performance -SURE Study
Recruiting NCT03087656 - Antibiotics to Decrease Post ERCP Cholangitis Phase 4
Completed NCT02098486 - Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP Phase 2
Withdrawn NCT03678480 - A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC) Phase 2
Recruiting NCT04216745 - Microbial Analysis in Patients With Cholangitis
Recruiting NCT03133026 - Cholangioscopic Assessment of Occluded Biliary Stent and Role of Biliary Radiofrequency Ablation N/A
Terminated NCT02618668 - Haemodynamic Stability of Ketamine/Propofol Admixture "Ketofol" in Patient Undergoing Endoscopic Retrograde Cholangio Pancreatography Phase 2
Recruiting NCT01438385 - Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders N/A
Recruiting NCT06111872 - Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography. Phase 2
Recruiting NCT05464303 - Definition for Biliary Atresia Associated Cholangitis After Surgery